Pancreatic Cancer Research

ResearcherChampalimaud FoundationActive in the last 2 years

Markus J. Maeurer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8436-8077; OpenAlex author ID A5006698445. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 12

  1. Tumor-Infiltrating Natural Killer Cell Characterization in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells15090797↗
  2. B Cells in the Gastrointestinal Tumor Microenvironment with a Focus on Pancreatic Cancer: Opportunities for Precision Medicine? Last author DOI 10.1007/978-3-030-49270-0_10↗
  3. Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. Last author DOI 10.1038/s41416-018-0262-z↗
  4. CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors. Last author DOI 10.1038/s41598-018-34710-2↗
  5. Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses. Last author DOI 10.18632/oncotarget.25121↗
  6. KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer. Last author DOI 10.3389/fonc.2018.00384↗
  7. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Co-author DOI 10.1002/1878-0261.12108↗
  8. A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. Co-author DOI 10.1097/cji.0000000000000164↗
  9. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. Last author DOI 10.1097/cji.0000000000000111↗
  10. Enhanced tumor-infiltrating lymphocytes (eTIL) for cellular therapy of patients with pancreatic cancer or glioblastoma Co-author DOI 10.1186/2051-1426-3-s2-p35↗
  11. A fast assay to gauge for TAA-reactive T cells in PBMCS from patients with pancreatic cancer Last author DOI 10.1186/2051-1426-2-s3-p25↗
  12. Generation of tumor-infiltrating lymphocytes from pancreatic cancer lesions for cellular therapy Last author DOI 10.1186/2051-1426-2-s3-p26↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingda Meng · 8 shared papers, 2014–2019 · strength 0.57
  2. Ernest Dodoo · 7 shared papers, 2014–2019 · strength 0.45
  3. Dário Ligeiro · 2 shared papers, 2020–2026 · strength 0.41
  4. Mireia Castillo-Martín · 2 shared papers, 2020–2026 · strength 0.41
  5. Andreia Maia · 2 shared papers, 2020–2026 · strength 0.41
  6. Elena B. Rangelova · 6 shared papers, 2014–2019 · strength 0.35
  7. Caroline Sophie Verbeke · 6 shared papers, 2014–2017 · strength 0.28
  8. Matthias J. Löhr · 5 shared papers, 2015–2018 · strength 0.27
  9. Marco Del Chiaro · 3 shared papers, 2016–2019 · strength 0.22
  10. Carlos Fernández Moro · 2 shared papers, 2017–2019 · strength 0.14
  11. Rainer Lothar Heuchel · 2 shared papers, 2017 · strength 0.10
  12. Johan Permert · 2 shared papers, 2017 · strength 0.10
  13. Elke Jäger · 1 shared paper, 2019 · strength 0.09
  14. Ann Morgell · 1 shared paper, 2018 · strength 0.07
  15. Nils Albiin · 1 shared paper, 2017 · strength 0.05
  16. Brigitta Omazic · 1 shared paper, 2017 · strength 0.05
  17. Olle T.H. Ringdén · 1 shared paper, 2017 · strength 0.05
  18. Nikolaos Kartalis · 1 shared paper, 2017 · strength 0.05
  19. Linnéa Malgerud · 1 shared paper, 2017 · strength 0.05
  20. Lars G. Engstrand · 1 shared paper, 2017 · strength 0.05
  21. Marco Del Chiaro · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.